Provexis plc (AIM:PXS)

Market Cap	24.68M +70.5%
Revenue (ttm)	1.26M -2.1%
Net Income	-502.76K
EPS	-0.00
Shares Out	2.35B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	152,139
Open	0.968
Previous Close	0.900
Day's Range	0.800 - 1.052
52-Week Range	0.550 - 1.550
Beta	0.68
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 30, 2026

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. It provides syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. The company also provides Fruitflow+ Omega-3, a dietary supplement product. It sells its products through e-commerce website and dis...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 2
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PXS

Financial Performance

In fiscal year 2026, Provexis's revenue was 1.26 million, a decrease of -2.14% compared to the previous year's 1.29 million. Losses were -502,760, 11.1% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error